Table 1.

Results of randomized clinical trials in Lenalidomide-refractory patients.

Treatments for first relapse in patients with lenalidomide-refractory disease
Trial	Phase	Agents	Outcome	References
OPTIMISMM	III	POM-Vd vs. Vd	Median PFS 11.2 vs. 7.1 months	[21]
A061202	II	POM-Kd	Median PFS 7.2 months Median OS 20.6 months	[23]
	I/II	POM-Kd	Median PFS 10.3 months 1 year OS 67%	[22]
CANDOR	III	Dara-Kd vs. Kd	Median PFS not reached vs. 15.8 months	[24]
IKEMA	III	Isa-Kd vs. Kd	Median PFS not reached vs. 19.1 months	[25]

POM pomalidomide, V velcade, bortezomib, d dexamethasone, Dara daratumumab, K carfilzomib, Isa Isatuximab.